Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P200007/S001

HeartSync Multifunction Disposable Single-Use AED Defibrillator Pads

Graphic Controls D.B.A. Vermed · Decision date Nov 12, 2025

FDA DECISIONP200007/S001

What did the FDA approve?

FDA records P200007/S001 as a supplement to PMA P200007, with the supplement type “135 Review Track For 30-Day Notice”. The recorded decision is approval, dated Nov 12, 2025.

FDA approval order statement

approval for an update to a manufacturing step of an intermediate component of the radiotransparent defibrillator pads
Regulatory pathway
PMA supplement
Supplement type
135 Review Track For 30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Nov 12, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P200007/S001
Regulatory pathway
PMA supplement
Product code
MKJ
Decision code
APPR
Decision date
Nov 12, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Automated external defibrillators (non-wearable).

Product code
MKJ
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P200007/S001 received

    Application receipt date recorded by FDA.

  2. P200007/S001 · FDA decision

    135 Review Track For 30-Day Notice

  3. P200007/S002 · Related supplement

    HeartSync Multifunction Disposable Single-Use Defibrillator Pads

Timeline entries are records held by MedtechLedger for P200007. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200007

Product / regulatory recordCompanyPathwayDecision dateSource
Graphic Controls D.B.A. VermedPMA supplementDec 19, 2025FDA

Explore the linked device profile

Other records with product code MKJ

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Graphic Controls D.B.A. Vermed

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
400 Exchange St., Buffalo, NY, 14204

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records